Publications


Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH. Budget impact analysis of tapentadol extended-release (ER) for the treatment of moderate to severe chronic pain. Clin Ther 2013;35:659-72.

Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R. Impact of solifenacin on quality of life, medical care use, work productivity and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatric Pharmacother 2009;7:373-382.

Noe L, Neil N, Ogden K, Turini M. Medical foods and foods for special medical purposes. Value Health 2009;12(7):A255 (Abstract).

Spalding J, Exuzides A, Colby C, Neil N, Noe L. Management of primary atrial fibrillation (AF): patient characteristics and hospital care setting. Value Health 2009;12(3):A153 (Abstract).

Spalding J, Exuzides A, Colby C, Neil N, Noe L. Inpatient resource use among patients treated for primary atrial fibrillation (AF): role of clinical factors and choice of initial conversion therapy. Value Health 2009;12(3):A153 (Abstract).

Spalding JR, Exuzides A, Adams S, Colby C, Noe L. Inpatient resource use associated with the treatment of secondary atrial fibrillation. Value Health 2008;11(6):A399 (Abstract).

Donohue JF, Hanania NA, Ciubotaru RL, Noe L, Pasta DJ, Schaefer K, Claus R, Andrews WT, Roach J. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clin Ther 2008;30:Theme Issue.

Belz M, Spalding J, Exuzides A, Adams S, Colby C, Noe L, Neil N. Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy. Value Health 2008;11(3):A200 (Abstract).

Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin 2008;24:1583-91.

Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008;23:2365-73.

Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro F. Economic evaluations of dialysis treatment modalities. Health Policy 2008;86:163-180.

Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro FT. Global economic evaluations of dialysis treatment modalities. Value Health 2007;10(6):A317 (Abstract).

Hansen R, Seifeldin R, Noe L. Medication adherence in post-transplant immunosuppression: the economic impact of drug-regimen complexity. Value Health. 2007;10(6):A368 (Abstract).

Hansen R, Seifeldin R, Noe L. Medication adherence in chronic disease: Issues in posttransplant immunosupprestion. Transplant Proc 2007;Jun;39(5):1287-300.

Pasta D, Silva S, Noe LL, Claus R, Schaefer K, Andrews W, Roach J. Quality-adjusted length of stay analysis of hospitalized patients with asthma or COPD treated with Levalbuterol or Racemic Albuterol. Value Health 2007;10(3):A110.

Claus R, Noe LL, Pasta D, Schaefer K, Andrews W, Roach J. Pharmacoeconomic outcomes of levalbuterol and racemic albuterol in hospitalized patients requiring nebulization therapy (POLARIS). Value Health 2007;10(3):A110.

Noe LL, Marshall TS, Rasouliyan L, Runken MC, Zinner NR. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly. Value Health 2007;10(3):A108.

Neil N, Block S, Ogden K, Noe LL, Black L, Williamson TE. Modeling the costs and outcomes of solifenacin vs. behavioral therapy or no therapy for treatment of overactive bladder in primary care. Pharmacotherapy 2005;25(10):1490.

Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Application of an algorithm for defining retrospective cohorts of colorectal cancer (CRC) patients treated with different first-line chemotherapy regiments +/- bevacizumab to administrative claims data. Value Health. 2005;8(6):A45.

Cisternas MG, Mrad R, Noe LL, Miller DP, Guyan C. Development of an algorithm for the identification and classification of colorectal cancer (CRC) patients according to first-line chemotherapy regiments +/- bevacizumab, and initiation of second-line therapy using administrative claims. Value Health. 2005;8(6):A45.

Neil N, Lamm D, Ogden K, Noe LL, Peterson L, Mallick R. A simulation model of the cost of treatment failure in patients hospitalized with community-acquired pneumonia (CAP) in the US. Clin Microbiol Infect. 2005;11(Suppl 2):O59.

Noe LL, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Managed Care Interface. 2004 Nov;54-60.

Becker RV, Noe LL, Chen DM, Williamson T. Evaluating the cost of long-acting treatments for overactive bladder. Value Health. 2002;5(6):583.

Noe LL, Becker RV, Chen DM, Williamson T. A straightforward cost-effectiveness analysis of long-acting treatments for overactive bladder: Can it be this simple? Value Health. 2002;5(6):582-3.

Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. JMCP. 2002;8(5):343-52.

Hufford MR, Noe L. Patient-Reported Outcomes: A Comparison of Two Data-Capture Methods. Value in Health 2001;4(6):(Abstract).

Becker R, Noe L, Gore M, Chen D. Using Level of Evidence Criteria in the Evaluation of Pharmacoeconomic Results. Value in Health 2001;4(6):(Abstract).

Becker R, Noe L, Gore M, Chen D. Incorporating Clinical Level-of-Evidence Criteria into a Breast Cancer Treatment Model for Japan. Value in Health 2001;4(6):(Abstract).

Becker R, Noe L, Gore M, Martino S. A new approach to disease modeling with numerous comparators and multiple decision trees. Value in Health 2001;4(2):189-190 (Abstract).

Noe L, Hankin CS. Health outcomes of childhood attention-deficit/hyperactivity disorder (ADHD): Health care use and work status of caregivers. Value in Health 2001;4(2):142-143 (Abstract).

Becker RV, Noe L, Gore M, Martino S, Eiermann W, Namer M, Howell A, Bianco A, Watanabe T. Disease modeling: Developing the infrastructure for a comprehensive, multi-national, clinical and economic breast cancer treatment model. Value in Health 2001;4(2):93 (Abstract).

Noe L. Impact of attention-deficit/hyperactivity disorder (ADHD) on healthcare use and work status: A survey of caregivers. J Managed Care Pharmacy 2001;7(2):133 (Abstract).

Kavanaugh A, Patel K, Bala M, Noe L. Cost-effectiveness of infliximab in rheumatoid arthritis. Arthritis Rheum 2000;43(9) Supplement: S144 (Abstract).

Noe L, Peeples P. Medical resource consumption by patients with chronic and breakthrough pain. Value in Health 2000;3(2):84 (Abstract).

Noe LL, Becker RV, Gore M, Martino S, Eiermann W, Namer M, Howell A, Bianco AR, Watanabe T, Chen DM. An approach to designing a multi-national model for the current treatment of breast cancer. Value in Health 2000;3(5):353 (Abstract).